|
|
Article: Jazz Pharmaceuticals Announces Phase III Clinical Trial to Study the Safety and Efficacy of Xyrem(R) (Sodium Oxybate) in Patients With Fibromyalgia Syndrome.
- Article from:
- PR Newswire
- Article date:
- September 7, 2006
CopyrightCOPYRIGHT 2006 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
PALO ALTO, Calif., Sept. 7 /PRNewswire/ -- Jazz Pharmaceuticals announced today the initiation of a Phase III clinical trial intended to evaluate the safety and efficacy of Xyrem(R) (sodium oxybate) oral solution as a treatment for fibromyalgia syndrome.
The randomized, double-blind, placebo-controlled study will evaluate the safety and efficacy of Xyrem compared to placebo for the treatment of fibromyalgia and its symptoms. The study will enroll both males and females, 18 years of age or older, who meet the American College of Rheumatology (ACR) diagnostic criteria for fibromyalgia.
Individuals who believe they may qualify to enroll in the study, or ...